Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;213(6):777-785.
doi: 10.1097/JU.0000000000004456. Epub 2025 Jan 27.

An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer

Eric H Kim  1   2 , Huaping Jing  3 , Kainen L Utt  3 , Joel M Vetter  4 , R Cody Weimholt  5 , Arnold D Bullock  4 , Alexandra P Klim  4 , Karla A Bergeron  4 , Jason K Frankel  6 , Zachary L Smith  7 , Gerald L Andriole  8 , Sheng-Kwei Song  3 , Joseph E Ippolito  3
Affiliations

An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer

Eric H Kim et al. J Urol. 2025 Jun.

Abstract

Purpose: Conventional prostate magnetic resonance imaging has limited accuracy for clinically significant prostate cancer (csPCa). We performed diffusion basis spectrum imaging (DBSI) before biopsy and applied artificial intelligence models to these DBSI metrics to predict csPCa.

Materials and methods: Between February 2020 and March 2024, 241 patients underwent prostate MRI that included conventional and DBSI-specific sequences before prostate biopsy. We used artificial intelligence models with DBSI metrics as input classifiers and the biopsy pathology as the ground truth. The DBSI-based model was compared with available biomarkers (PSA, PSA density [PSAD], and Prostate Imaging Reporting and Data System [PI-RADS]) for risk discrimination of csPCa defined as Gleason score > 7.

Results: The DBSI-based model was an independent predictor of csPCa (odds ratio [OR] 2.04, 95% CI 1.52-2.73, P < .01), as were PSAD (OR 2.02, 95% CI 1.21-3.35, P = .01) and PI-RADS classification (OR 4.00, 95% CI 1.37-11.6 for PI-RADS 3, P = .01; OR 9.67, 95% CI 2.89-32.7 for PI-RADS 4-5, P < .01), adjusting for age, family history, and race. Within our dataset, the DBSI-based model alone performed similarly to PSAD + PI-RADS (AUC 0.863 vs 0.859, P = .89), while the combination of the DBSI-based model + PI-RADS had the highest risk discrimination for csPCa (AUC 0.894, P < .01). A clinical strategy using the DBSI-based model for patients with PI-RADS 1-3 could have reduced biopsies by 27% while missing 2% of csPCa (compared with biopsy for all).

Conclusions: Our DBSI-based artificial intelligence model accurately predicted csPCa on biopsy and can be combined with PI-RADS to potentially reduce unnecessary prostate biopsies.

Keywords: MRI; PSA; biomarkers; prostate cancer.

PubMed Disclaimer

References

    1. Kim EH, Andriole GL. Prostate-specific antigen-based screening: controversy and guidelines. BMC Medicine 2015; 13: 1–4. - PMC - PubMed
    1. Bjurlin MA, Carroll PR, Eggener S, et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. J Urol 2020; 203: 706–712. - PMC - PubMed
    1. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging-reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16–40. - PMC - PubMed
    1. Hamoen EHJ, de Rooij M, Witjes JA, et al. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. Eur Urol 2015; 67: 1112–1121. - PubMed
    1. Zhang L, Tang M, Chen S, et al. A meta-analysis of use of prostate imaging reporting and data system version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol 2017; 27: 5204–5214. - PubMed